Court Report

By Sherri Oslick --

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

AbbVie Inc. v. Hetero USA Inc. et al.
1:13-cv-00852; filed May 15, 2013 in the District Court of Delaware

• Plaintiff:  AbbVie Inc.
• Defendants:  Hetero USA Inc.; Hetero Labs Ltd.

Infringement of U.S. Patent Nos. 7,148,359 ("Polymorph of a Pharmaceutical," issued December 12, 2006), 7,364,752 ("Solid Dispersion Pharmaceutical Formulations," issued April 29, 2008), 8,268,349 ("Solid Pharmaceutical Dosage Form," issued September 18, 2012), 6,037,157 ("Method for Improving Pharmacokinetics," issued March 14, 2000), and 6,703,403 (same title, issued March 9, 2004) following a Paragraph IV certification as part of Hetero's filing of an ANDA to manufacture a generic version of AbbVie's Norvir® (ritonavir, used to treat human immunodeficiency virus (HIV) infection).  View the complaint here.

Senju Pharmaceutical Co. Ltd. et al. v. Strides Inc. et al.
1:13-cv-00851; filed May 15, 2013 in the District Court of Delaware

• Plaintiffs:  Senju Pharmaceutical Co. Ltd.; Kyorin Pharmaceutical Co. Ltd.; Allergan Inc.
• Defendants:  Strides Inc.; Agila Specialties Private Ltd.

Infringement of U.S. Patent No. 6,333,045 ("Aqueous Liquid Pharmaceutical Composition Comprised of Gatifloxacin," issued December 25, 2001) following a Paragraph IV certifications as part of defendants' filing of an ANDA to manufacture a generic version of Allergan's Zymar® (0.3 w/v % gatifloxacin ophthalmic solution, used for the treatment of bacterial conjunctivitis) and of Allergan's Zymaxid® (0.5 w/v % gatifloxacin ophthalmic solution, used to treat bacterial conjunctivitis).  View the complaint here.

Endo Pharmaceuticals, Inc. v. Par Pharmaceutical Companies, Inc. et al.
1:13-cv-03284; filed May 15, 2013 in the Southern District of New Yorkk

• Plaintiff:  Endo Pharmaceuticals, Inc.
• Defendants:  Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.

Endo Pharmaceuticals Inc. v. Sandoz Inc.
1:13-cv-03287; filed May 15, 2013 in the Southern District of New York

Endo Pharmaceuticals Inc. v. Roxane Laboratories, Inc.
1:13-cv-03288; filed May 15, 2013 in the Southern District of New York

Endo Pharmaceuticals Inc. v. Mallinckrodt LLC
1:13-cv-03288; filed May 15, 2013 in the Southern District of New York

Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. et al.
1:13-cv-03288; filed May 15, 2013 in the Southern District of New York

• Plaintiff:  Endo Pharmaceuticals, Inc.
• Defendants:  Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries Ltd.; Barr Laboratories, Inc.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 7,851,482 ("Method for Making Analgesics," issued December 14, 2010), 8,309,122 ("Oxymorphone Controlled Release Formulations," issued November 13, 2012), and 8,329,216 (same title, issued December 11, 2012) following a Paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of Endo's Opana® ER CRF (oxymorphone hydrochloride, crush-resistant formulation, used to treat moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time).  View the Par complaint here.

Bayer Pharma AG et al. v. Par Pharmaceutical Inc. et al.
1:13-cv-00845; filed May 14, 2013 in the District Court of Delaware

• Plaintiffs:  Bayer Pharma AG; Bayer Intellectual Property GmbH; Bayer HealthCare Pharmaceuticals Inc.
• Defendants:  Par Pharmaceutical Inc.; Par Pharmaceutical Companies Inc.

Infringement of U.S. Patent Nos. 6,362,178 ("2-phenyl Substituted Imidazotriazinones as Phosphodiesterase Inhibitors," issued March 26, 2002) and 7,696,206 (same title, issued April 13, 2010) following a Paragraph IV certification as part of Par's filing of an ANDA to manufacture a generic version of plaintiffs' Staxyn® (vardenafil hydrochloride, used to treat erectile dysfunction).  View the complaint here.

Astrazeneca AB et al. v. Watson Laboratories, Inc.- Florida et al.
3:13-cv-03038; filed May 10, 2013 in the District Court of New Jersey

• Plaintiffs:  Astrazeneca AB; Astrazeneca LP; KBI-E Inc.; Pozen, Inc.
• Defendants:  Watson Laboratories, Inc.- Florida; Watson Pharma, Inc.; Actavis, Inc.

Infringement of U.S. Patent Nos. 5,714,504 ("Compositions," issued February 3, 1988), 6,369,085 ("Form of S-omeprazole," issued April 9, 2002), 6,875,872 ("Compounds," issued April 5, 2005), 7,411,070 ("same title," issued August 12 ,2008), and 7,745,466 (same title, issued June 29, 2010) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of AstraZeneca's Vimovo® (naproxen and esomeprazole magnesium, used to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with non-steroidal anti-inflammatory drugs (NSAIDs)).  View the complaint here.

Purdue Pharma L.P. et al. v. Impax Laboratories, Inc.
1:13-cv-03188; filed May 10, 2013 in the Southern District of New York

• Plaintiffs:  Purdue Pharma L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.
• Defendant:  Impax Laboratories, Inc.

Infringement of U.S. Patent No. 8,337,888 ("Pharmaceutical Formulation Containing Gelling Agent," issued December 25, 2012) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain).  View the complaint here.